As the consumer group splits away today, what will New GSK buy now?

What a difference one really good Phase III readout and a couple of late-stage buyouts can make.

GSK CEO Emma Walmsley has been trying, hard, to build some excitement around the pipeline. And with the recent positive outcome for their RSV vaccine, she’s finally earning some market respect on that score. And with the big consumer split today, with the birth of Haleon, you can expect plenty of buzz about the need for another M&A deal to position the company.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE

TRENDING NOW

As the consumer group splits away today, what will New GSK buy now?

This article is for premium subscribers only

The next generation of AI biotechs is here. Can they deliver on the hype?

AbbVie beats first-quarter expectations, but Humira guidance leaves analysts confused

UCB makes major management changes; Bristol Myers’ ADC partner tops list of new CEOs

Updated: FDA approves Pfizer’s hemophilia B gene therapy, with $3.5M price tag

Bristol Myers to shutter Bay Area cell therapy facility as it eliminates jobs and costs

Ophthalmic biotech raises $16.5M; Pfizer’s AI collaboration bears fruit

As the con­sumer group splits away to­day, what will New GSK buy now?

This article is for premium subscribers only

more like this

The next gen­er­a­tion of AI biotechs is here. Can they de­liv­er on the hype?

Ab­b­Vie beats first-quar­ter ex­pec­ta­tions, but Hu­mi­ra guid­ance leaves an­a­lysts con­fused

UCB makes ma­jor man­age­ment changes; Bris­tol My­ers’ ADC part­ner tops list of new CEOs

Up­dat­ed: FDA ap­proves Pfiz­er’s he­mo­phil­ia B gene ther­a­py, with $3.5M price tag

Bris­tol My­ers to shut­ter Bay Area cell ther­a­py fa­cil­i­ty as it elim­i­nates jobs and costs

Oph­thalmic biotech rais­es $16.5M; Pfiz­er’s AI col­lab­o­ra­tion bears fruit

As the consumer group splits away today, what will New GSK buy now?

The next generation of AI biotechs is here. Can they deliver on the hype?

AbbVie beats first-quarter expectations, but Humira guidance leaves analysts confused

UCB makes major management changes; Bristol Myers’ ADC partner tops list of new CEOs

Updated: FDA approves Pfizer’s hemophilia B gene therapy, with $3.5M price tag

Bristol Myers to shutter Bay Area cell therapy facility as it eliminates jobs and costs

Ophthalmic biotech raises $16.5M; Pfizer’s AI collaboration bears fruit